600276 恒瑞医药
已收盘 05-08 15:00:00
资讯
新帖
简况
多家药企高管生变：恒瑞、复星、阿斯利康、辉瑞…
赛柏蓝 · 05-07 19:53
多家药企高管生变：恒瑞、复星、阿斯利康、辉瑞…
恒瑞医药已回购1206万股 金额7.72亿元
财中社 · 05-07 16:45
恒瑞医药已回购1206万股 金额7.72亿元
又有国内药企公布积极研究数据，减肥药如何“卷”出差异化？
澎湃新闻 · 05-07 16:15
又有国内药企公布积极研究数据，减肥药如何“卷”出差异化？
花旗集团增持恒瑞医药H股 持股比例从6.68%升至7.48%
美股速递 · 05-04
花旗集团增持恒瑞医药H股 持股比例从6.68%升至7.48%
14款1类新药在中国获批临床！来自长风药业(02652)、恒瑞医药(01276)等
智通财经网 · 05-03
14款1类新药在中国获批临床！来自长风药业(02652)、恒瑞医药(01276)等
交银国际：升恒瑞医药(01276)目标价至74港元 首季业绩延续高增长态势
智通财经 · 04-27
交银国际：升恒瑞医药(01276)目标价至74港元 首季业绩延续高增长态势
创新成果持续落地、国际化再迎里程碑，挖掘恒瑞医药(01276)一季报背后的投资确定性
智通财经 · 04-27
创新成果持续落地、国际化再迎里程碑，挖掘恒瑞医药(01276)一季报背后的投资确定性
花旗：恒瑞医药给予“买入”评级 目标价134港元
新浪港股 · 04-25
花旗：恒瑞医药给予“买入”评级 目标价134港元
瑞银：升恒瑞医药(01276)目标价至97.4港元 维持“买入”评级
智通财经 · 04-24
瑞银：升恒瑞医药(01276)目标价至97.4港元 维持“买入”评级
T3出行、明珠化工、圆心科技递表港交所主板；平安好医生、中国电信、恒瑞医药发布一季度报告丨港交所早参
每日经济新闻 · 04-24
T3出行、明珠化工、圆心科技递表港交所主板；平安好医生、中国电信、恒瑞医药发布一季度报告丨港交所早参
恒瑞医药：二级市场波动受多重因素影响
证券日报 · 04-23
恒瑞医药：二级市场波动受多重因素影响
港股异动 | 恒瑞医药(01276)绩后涨超5% 一季度归母净利同比增加21.78%
智通财经 · 04-23
港股异动 | 恒瑞医药(01276)绩后涨超5% 一季度归母净利同比增加21.78%
港股公告掘金 | 恒瑞医药一季度归母净利润同比增加21.78% 赛力斯拟回购最多20亿元A股
智通财经 · 04-23
港股公告掘金 | 恒瑞医药一季度归母净利润同比增加21.78% 赛力斯拟回购最多20亿元A股
智通港股早知道 | 中办、国办：持续推进绿色交通基础设施建设 恒瑞医药(01276)一季度归母净利润同比增加21.78%
智通财经 · 04-23
智通港股早知道 | 中办、国办：持续推进绿色交通基础设施建设 恒瑞医药(01276)一季度归母净利润同比增加21.78%
创新药收入占比首破六成，恒瑞医药Q1营收81亿元，净利同增22%
华尔街见闻 · 04-22
创新药收入占比首破六成，恒瑞医药Q1营收81亿元，净利同增22%
恒瑞医药：第一季度净利润22.82亿元，同比增长21.78%
每日经济新闻 · 04-22
恒瑞医药：第一季度净利润22.82亿元，同比增长21.78%
恒瑞医药(01276)：HRS9531注射液获得药物临床试验批准通知书
智通财经 · 04-20
恒瑞医药(01276)：HRS9531注射液获得药物临床试验批准通知书
恒瑞医药将于5月27日派发末期股息每10股2元
新浪港股 · 04-20
恒瑞医药将于5月27日派发末期股息每10股2元
减肥药企业Kailera纳斯达克上市：市值31亿美元 恒瑞医药成大赢家
雷递网 · 04-19
减肥药企业Kailera纳斯达克上市：市值31亿美元 恒瑞医药成大赢家
恒瑞医药(01276)将于5月27日派发末期股息每10股2元
智通财经 · 04-17
恒瑞医药(01276)将于5月27日派发末期股息每10股2元
暂无数据
公司概况
公司名称：
江苏恒瑞医药股份有限公司
所属行业：
医药制造业
上市日期：
2000-10-18
主营业务：
江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
发行价格：
11.98
{"stockData":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":52.8,"timestamp":1778223600000,"preClose":53.68,"halted":0,"volume":80241465,"delay":0,"changeRate":-0.0164,"floatShares":6379000000,"shares":6637000000,"eps":1.2233,"marketStatus":"已收盘","change":-0.88,"latestTime":"05-08 15:00:00","open":53.88,"high":53.92,"low":52.68,"amount":4254000000,"amplitude":0.0231,"askPrice":52.8,"askSize":71,"bidPrice":52.79,"bidSize":287,"shortable":0,"etf":0,"ttmEps":1.2233,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778463000000},"marketStatusCode":5,"adr":0,"adjPreClose":53.68,"symbolType":"stock","openAndCloseTimeList":[[1778203800000,1778211000000],[1778216400000,1778223600000]],"highLimit":59.05,"lowLimit":48.31,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6637199874,"isCdr":false,"pbRate":5.51,"roa":"--","peRate":43.161939,"roe":"4.15%","epsLYR":1.19,"committee":0.098652,"marketValue":350444000000,"turnoverRate":0.0126,"status":1,"hkstockBrief":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":64.55,"timestamp":1778227683002,"preClose":65.55,"halted":0,"volume":1988645,"delay":0,"premium":"+6.16"},"floatMarketCap":336811000000},"requestUrl":"/m/hq/s/600276/tweets","defaultTab":"tweets","newsList":[{"id":"2633794147","title":"多家药企高管生变：恒瑞、复星、阿斯利康、辉瑞…","url":"https://stock-news.laohu8.com/highlight/detail?id=2633794147","media":"赛柏蓝","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633794147?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:53","pubTimestamp":1778154780,"startTime":"0","endTime":"0","summary":"01本土制药企业与Biotech迎高管变动恒瑞医药、再鼎医药、百济神州、和铂医药、复星医药映射出了中国创新药发展过程中企业所处的不同阶段。4月16日，恒瑞医药发布公告，正式完成新一届董事会和管理层聘任。复星医药4月2日，复星医药发布首席财务官变更公告，因工作安排调整，陈战宇辞去首席财务官职务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-07/doc-inhxatff4708181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ONC","AZNH","LU1057294990.SGD","LU0225771236.USD","SG9999001176.SGD","BK4588","LU0456855351.SGD","SG9999003800.SGD","BK4568","IE00BLSP4239.USD","LU0234572021.USD","LU0289739699.SGD","IE00B3T34201.USD","BK4585","LU2456880835.USD","BK4533","LU0321505439.SGD","LU2417539215.USD","IE00BBT3K403.USD","600276","LU2462157665.USD","02196","LU0306807586.USD","LU0321505868.SGD","LU2236285917.USD","LU0122379950.USD","LU2237443978.SGD","SG9999013999.USD","SGXZ57979304.SGD","02142","LU0170899867.USD","SG9999011175.SGD","LU2237443382.USD","LU0058720904.USD","LU0868494617.USD","SG9999001176.USD","LU1066051498.USD","LU2237443549.SGD","LU0109394709.USD","SG9999002224.SGD","IE00B19Z3581.USD","BK4581","BK4534","IE0002270589.USD","06160","LU1883839398.USD","BK4599","01276","BK4592","LU0225284248.USD","LU1829250122.USD","600196","BK4007","LU1894683264.USD","688235","LU2237443895.HKD","PFE","SG9999002232.USD","BK4550","LU2237443622.USD","IE00BLSP4452.SGD","IE000M9KFDE8.USD","LU0985481810.HKD","LU0306806265.USD","LU0320765992.SGD","LU2237443465.HKD","AZN","LU1023059063.AUD","IE00B19Z3B42.SGD","LU1066053197.SGD","LU1894683348.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633119513","title":"恒瑞医药已回购1206万股 金额7.72亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633119513","media":"财中社","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633119513?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:45","pubTimestamp":1778143500,"startTime":"0","endTime":"0","summary":"5月7日，恒瑞医药（600276/01276）发布公告，截至2026年4月30日已回购1206万股，占总股本的0.18%，回购金额为7.72亿元，回购价格区间为53.52元/股至70元/股。2026年一季度，恒瑞医药实现收入0.0元，归母净利润22.82亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605073730120976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0012","LU0405327494.USD","LU1064130708.USD","BK0060","LU1820825898.SGD","LU0359201885.HKD","LU0359202008.SGD","LU1997245177.USD","LU2328871848.SGD","BK0239","LU1580142542.USD","LU2289578879.USD","LU2543165471.USD","LU2580892862.HKD","LU2097828714.EUR","LU1023057109.AUD","LU1146622755.USD","LU2097828631.EUR","LU1969619763.USD","LU2097828474.EUR","LU1064131003.USD","LU1255011170.USD","LU1997245094.SGD","LU1328615791.USD","LU2488822045.USD","LU0405327148.USD","LU2097828805.USD","BK0028","LU1997244956.HKD","01276","LU0359201612.USD","600276","BK0183","LU1781817850.SGD","LU2495084118.USD","LU1655091616.SGD","BK0196","LU2580892789.USD","LU2148510915.USD","LU2097828557.USD","BK1191","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633115292","title":"又有国内药企公布积极研究数据，减肥药如何“卷”出差异化？","url":"https://stock-news.laohu8.com/highlight/detail?id=2633115292","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633115292?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:15","pubTimestamp":1778141700,"startTime":"0","endTime":"0","summary":"在两大减肥药巨头公布一季报之际，多家手握减肥药管线的国内外药企也相继公布研究进展。5月5日，博瑞生物医药（苏州）股份有限公司（博瑞医药，688166）宣布，其自主研发BGM0504注射液在一项旨在评估其在超重或肥胖受试者中有效性和安全性的三期临床研究中取得积极顶线结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605073730075275.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605073730075275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","LU2289578879.USD","603087","LU1820825898.SGD","LU1969619763.USD","LU0405327494.USD","LU2580892789.USD","LU1997245177.USD","BK0196","BK0012","LU2097828631.EUR","LU0405327148.USD","LU2488822045.USD","LU1328615791.USD","LU2097828557.USD","LU1997245094.SGD","LU2495084118.USD","LU1655091616.SGD","LU1146622755.USD","LU1064131003.USD","LU2097828805.USD","LU1255011170.USD","LU2148510915.USD","LU1781817850.SGD","BK0028","600276","LU1997244956.HKD","LU1580142542.USD","LU2328871848.SGD","BK0183","LU1064130708.USD","LU2097828474.EUR","LU2097828714.EUR","BK0188","LU2580892862.HKD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135325932","title":"花旗集团增持恒瑞医药H股 持股比例从6.68%升至7.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135325932","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135325932?lang=zh_cn&edition=full","pubTime":"2026-05-04 18:07","pubTimestamp":1777889223,"startTime":"0","endTime":"0","summary":"根据香港交易所最新披露文件显示，花旗集团对江苏恒瑞医药H股的持股比例出现显著变动。截至4月27日，该机构持有的多头头寸已从原先的6.68%提升至7.48%，增幅达0.8个百分点。\n此次持股比例的上调反映出国际金融机构对中国医药龙头企业的持续看好。作为国内创新药领域的标杆企业，恒瑞医药始终受到全球投资者的密切关注。花旗集团此次增持动作，可能预示着其对该公司长期发展前景的积极预期。\n资本市场专业人士指出，机构投资者持股比例的变动往往被视为重要的市场风向标。此次持股比例突破7%的关键点位，不仅体现了外资对中国医药行业的信心，也可能对二级市场投资情绪产生正向影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1328615791.USD","LU2328871848.SGD","LU1255011170.USD","LU1655091616.SGD","BK0239","LU0359202008.SGD","BK0196","LU2495084118.USD","LU1781817850.SGD","LU0359201885.HKD","600276","LU2097828557.USD","LU2580892789.USD","LU1146622755.USD","BK0183","LU0359201612.USD","LU2097828805.USD","LU2097828714.EUR","BK0188","LU1064131003.USD","LU1580142542.USD","LU1997244956.HKD","LU2543165471.USD","LU1064130708.USD","BK0060","LU0405327148.USD","LU1997245177.USD","LU1997245094.SGD","LU2097828474.EUR","LU2488822045.USD","BK1191","LU1820825898.SGD","BK0028","LU0405327494.USD","LU1023057109.AUD","LU1969619763.USD","BK0012","LU2580892862.HKD","LU2289578879.USD","01276","LU2097828631.EUR","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632601701","title":"14款1类新药在中国获批临床！来自长风药业(02652)、恒瑞医药(01276)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2632601701","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632601701?lang=zh_cn&edition=full","pubTime":"2026-05-03 16:39","pubTimestamp":1777797543,"startTime":"0","endTime":"0","summary":"上周(4月27日~5月2日)，有14款1类创新药首次在中国获得临床试验默示许可(IND)。这些产品涵盖小分子、多肽、抗体、抗体偶联药物(ADC)等等。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260503/20260503163939_45803.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260503/20260503163939_45803.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0359201885.HKD","LU2488822045.USD","LU1997245177.USD","LU2148510915.USD","LU1328615791.USD","600276","BK0183","LU0359201612.USD","LU2289578879.USD","LU1580142542.USD","LU2328871848.SGD","LU1064130708.USD","LU2097828631.EUR","LU1655091616.SGD","LU1997245094.SGD","BK0188","LU0405327148.USD","01276","LU2580892789.USD","LU2097828474.EUR","LU1997244956.HKD","BK0028","LU2097828557.USD","LU1820825898.SGD","LU1146622755.USD","BK0239","LU2580892862.HKD","BK0060","BK1191","LU1064131003.USD","LU2097828805.USD","LU2543165471.USD","LU0405327494.USD","LU2097828714.EUR","LU0359202008.SGD","LU1255011170.USD","02652","BK0012","LU1969619763.USD","LU1023057109.AUD","BK0196","LU1781817850.SGD","LU2495084118.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630368994","title":"交银国际：升恒瑞医药(01276)目标价至74港元 首季业绩延续高增长态势","url":"https://stock-news.laohu8.com/highlight/detail?id=2630368994","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630368994?lang=zh_cn&edition=full","pubTime":"2026-04-27 15:06","pubTimestamp":1777273611,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，恒瑞医药首季业绩延续去年的高增长态势，创新药尤其是非肿瘤产品快速放量，在整体产品销售中的比例超过60%，创新转型已基本成功。基于首季业绩表现，交银国际上调恒瑞医药2026至2028年利润率预测，上调净利润预测3%至4%，并认为公司当前估值合理，上调目标价至74港元，维持“中性”评级。报告指，恒瑞医药首季收入/扣非净利润分别增长13%/17%，整体业绩略超该行此前的预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630847355","title":"创新成果持续落地、国际化再迎里程碑，挖掘恒瑞医药(01276)一季报背后的投资确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2630847355","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630847355?lang=zh_cn&edition=full","pubTime":"2026-04-27 10:28","pubTimestamp":1777256930,"startTime":"0","endTime":"0","summary":"4月22日晚，恒瑞医药正式发布了2026年第一季度经营业绩。而在临床研发方面，恒瑞医药今年一季度累计取得临床试验批准通知26个;2026年以来获得CDE突破性治疗品种认定6项。报告期内，公司创新药对外许可业务确认收入7.87亿元，主要系GSK确认的收入。近期，恒瑞医药国际化发展迎来新的里程碑。此前，Kailera公司已向恒瑞医药支付了1亿美元不可退还首付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1328615791.USD","LU2328871848.SGD","LU1255011170.USD","LU1655091616.SGD","BK0239","LU0359202008.SGD","BK0196","LU2495084118.USD","LU1781817850.SGD","LU0359201885.HKD","600276","LU2097828557.USD","LU2580892789.USD","LU1146622755.USD","BK0183","LU0359201612.USD","LU2097828805.USD","LU2097828714.EUR","BK0188","LU1064131003.USD","LU1580142542.USD","LU1997244956.HKD","LU2543165471.USD","LU1064130708.USD","BK0060","LU0405327148.USD","LU1997245177.USD","LU1997245094.SGD","LU2097828474.EUR","LU2488822045.USD","BK1191","LU1820825898.SGD","BK0028","LU0405327494.USD","LU1023057109.AUD","LU1969619763.USD","BK0012","LU2580892862.HKD","LU2289578879.USD","01276","LU2097828631.EUR","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630879944","title":"花旗：恒瑞医药给予“买入”评级 目标价134港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630879944","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630879944?lang=zh_cn&edition=full","pubTime":"2026-04-25 10:15","pubTimestamp":1777083300,"startTime":"0","endTime":"0","summary":" 花旗发布研报称，给予恒瑞医药H股目标价134港元以及“买入”评级。花旗指出，恒瑞医药2026年第一季创新药销售年增26%至45亿元人民币，占产品销售比重由去年同期的54%提升至62%。 公司管理层重申2026年创新药销售年增超过30%的目标，并指出3月医院准入加速，为全年销售增长奠定基础。公司2026年第一季确认来自葛兰素史克合作的BD收入7.87亿元人民币，全年预计约2.5亿元人民币。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-04-25/doc-inhvsqpe7283823.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600276","EWH","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629950788","title":"瑞银：升恒瑞医药(01276)目标价至97.4港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2629950788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629950788?lang=zh_cn&edition=full","pubTime":"2026-04-24 10:54","pubTimestamp":1776999295,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，基于2026年第一季业绩，由于研发进展，上调恒瑞医药(01276)长期销售预测。目标价由91港元升至97.4港元，维持“买入”评级。恒瑞医药首季营收同比增13%至81.4亿元人民币，略低于市场预测85.3亿元人民币及该行预测88.1亿元人民币;净利润增长21.8%至22.8亿元人民币，大致符合市场预测21.8亿元人民币及该行预测23.3亿元人民币。第一季毛利率同比增1.4个百分点至86.6%; 净利润率上升2个百分点至28%。第一季研发投资达22.2亿人民币，其中16.5亿元人民币计入费用;销售费用率下降0.3个百分点至27%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433204.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","01276","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629864397","title":"T3出行、明珠化工、圆心科技递表港交所主板；平安好医生、中国电信、恒瑞医药发布一季度报告丨港交所早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2629864397","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629864397?lang=zh_cn&edition=full","pubTime":"2026-04-24 07:00","pubTimestamp":1776985211,"startTime":"0","endTime":"0","summary":"｜2026年4月24日星期五｜NO.1T3出行、明珠化工、圆心科技递表港交所主板据港交所4月22日消息，南京领行科技股份有限公司（以下简称T3出行）、湖南明珠矿用化工科技股份有限公司（以下简称明珠化工）、北京圆心科技集团股份有限公司（以下简称圆心科技）已向港交所主板提交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604243716838768.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604243716838768.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0039217434.USD","BK1617","LU2328871848.SGD","01833","LU2097828805.USD","SGXZ49509284.SGD","600276","BK1142","BK0060","BK1219","LU1969619763.USD","LU2495084118.USD","LU2488822045.USD","601728","LU1820825898.SGD","BK1589","LU2097828474.EUR","LU1064130708.USD","BK0028","HK0000288784.HKD","00728","LU1255011170.USD","LU2148510915.USD","LU1146622755.USD","LU1997245094.SGD","LU1997245177.USD","BK1610","LU2580892862.HKD","LU1580142542.USD","BK1536","HK0000352382.USD","BK1191","LU0359201885.HKD","LU2289578879.USD","BK0261","BK0239","BK1247","IPOS","LU0405327494.USD","01276","LU1781817850.SGD","BK1506","LU2097828557.USD","LU2580892789.USD","LU1328615791.USD","LU2543165471.USD","BK1615","LU2097828631.EUR","HK0000352291.HKD","LU1655091616.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629836502","title":"恒瑞医药：二级市场波动受多重因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2629836502","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629836502?lang=zh_cn&edition=full","pubTime":"2026-04-23 19:19","pubTimestamp":1776943140,"startTime":"0","endTime":"0","summary":"证券日报网讯4月23日，恒瑞医药在互动平台回答投资者提问时表示，二级市场波动受多重因素影响。公司目前经营稳定，严守合规底线，高标准、严要求、全方位打造合规文化，不断巩固合规意识，确保全面高质量合规，推动公司业务可持续发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233716339814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0028","LU0405327494.USD","LU2580892862.HKD","LU1255011170.USD","LU2488822045.USD","BK1191","BK0196","BK0012","BK0239","LU0359201612.USD","LU1328615791.USD","LU1820825898.SGD","BK0060","LU2097828714.EUR","LU2495084118.USD","LU1064130708.USD","BK0183","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","LU2328871848.SGD","LU0405327148.USD","LU1997244956.HKD","LU2148510915.USD","LU2097828557.USD","LU2289578879.USD","01276","LU1969619763.USD","LU1781817850.SGD","LU1023057109.AUD","LU1997245177.USD","LU2097828631.EUR","LU2097828805.USD","LU1146622755.USD","600276","LU1064131003.USD","LU1655091616.SGD","LU2097828474.EUR","LU2580892789.USD","LU1997245094.SGD","BK0188","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629607068","title":"港股异动 | 恒瑞医药(01276)绩后涨超5% 一季度归母净利同比增加21.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629607068","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629607068?lang=zh_cn&edition=full","pubTime":"2026-04-23 09:36","pubTimestamp":1776908175,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，恒瑞医药绩后涨超5%，截至发稿，涨3.22%，报68.85港元，成交额1.35亿港元。消息面上，4月22日，恒瑞医药发布公告，于2026年第一季度，该集团取得营业收入人民币81.41亿元，同比增加12.98%；归属于上市公司股东的净利润22.82亿元，同比增加21.78%；基本每股收益0.34元。2026年第一季度，公司创新药销售收入45.26亿元，同比增长 25.75%，占药品销售收入的比重达61.69%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1997245094.SGD","LU0405327494.USD","LU2543165471.USD","LU1328615791.USD","LU2289578879.USD","LU1023057109.AUD","LU2097828557.USD","LU0359201885.HKD","BK4585","BK0183","LU1064130708.USD","BK1191","LU1255011170.USD","LU2580892789.USD","BK0188","LU2097828474.EUR","VXUS","LU1655091616.SGD","BK0239","LU2097828714.EUR","LU2488822045.USD","LU1781817850.SGD","LU1820825898.SGD","LU0359201612.USD","LU2097828631.EUR","LU0359202008.SGD","LU2097828805.USD","BK0012","BK0028","BK0196","LU1997244956.HKD","LU2328871848.SGD","BK4588","600276","LU1146622755.USD","LU2148510915.USD","01276","LU2495084118.USD","LU1064131003.USD","LU1580142542.USD","BK0060","LU1997245177.USD","LU0405327148.USD","LU1969619763.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629608077","title":"港股公告掘金 | 恒瑞医药一季度归母净利润同比增加21.78% 赛力斯拟回购最多20亿元A股","url":"https://stock-news.laohu8.com/highlight/detail?id=2629608077","media":"智通财经","labels":["shareholding","dataReport","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629608077?lang=zh_cn&edition=full","pubTime":"2026-04-23 09:03","pubTimestamp":1776906229,"startTime":"0","endTime":"0","summary":"【重大事项】华勤技术(03296)：香港公开发售获531.33倍认购 每股发售价77.7港元赛力斯(09927)拟回购10亿-20亿元的A股 助力价值回归博泰车联(02889)与地平线签署战略合作协议 共同打造汽车智能化、国产化的平台级解决方案康耐特光学(02276)与一家在智能眼镜领域占据行业领导地位的全球领先科技企业签署合作备忘录达力普控股(01921)附属拟引入库卡AI智能机器人技术 积极推","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09927","LU2488822045.USD","LU2517655291.USD","BK0012","LU2543165471.USD","LU0871576103.HKD","LU1064130708.USD","IE0034224299.USD","SG9999001093.SGD","BK0183","BK1596","LU2517655374.HKD","LU0039217434.USD","LU1997245094.SGD","SG9999001051.SGD","BK0188","SG9999001069.SGD","SG9999006597.SGD","BK0028","BK1519","LU2495084118.USD","LU0307460666.USD","BK4585","BK1193","LU0359202008.SGD","BK1109","LU2097828474.EUR","LU2328871848.SGD","LU1064131003.USD","LU1997245177.USD","LU1880383440.USD","LU0594300419.USD","LU0531971595.HKD","LU1781817850.SGD","LU1969619763.USD","LU1655091616.SGD","LU1580142542.USD","LU1023057109.AUD","BK0185","BK0196","LU2148510915.USD","601127","LU0359201612.USD","LU0605514214.HKD","LU1255011170.USD","LU2097828714.EUR","BK1588","BK0014","BK0264","LU0405327148.USD","SG9999002950.SGD","LU0405327494.USD","BK1228","LU1328615791.USD","LU2289578879.USD","LU1820825898.SGD","LU2580892789.USD","BK0239","600276","LU0594300179.USD","BK0060","BK4588","LU2097828557.USD","01276","BK1095","BK1119","LU1880383366.USD","LU2580892862.HKD","LU1146622755.USD","BK1191","LU1997244956.HKD","LU2097828631.EUR","BK1556","BK0201","LU0588546209.SGD","LU2097828805.USD","LU2517655028.SGD","LU0650527681.SGD","LU0164865239.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629071540","title":"智通港股早知道 | 中办、国办：持续推进绿色交通基础设施建设 恒瑞医药(01276)一季度归母净利润同比增加21.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629071540","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629071540?lang=zh_cn&edition=full","pubTime":"2026-04-23 07:22","pubTimestamp":1776900146,"startTime":"0","endTime":"0","summary":"恒瑞医药发布第一季度业绩，归母净利润22.82亿元 同比增加21.78%恒瑞医药发布公告，于2026年第一季度，该集团取得营业收入人民币81.41亿元，同比增加12.98%；归属于上市公司股东的净利润22.82亿元，同比增加21.78%；基本每股收益0.34元。经营利润同比上升44.8%至1.803亿美元。截至2026年2月28日止首九个月，净营收为41.318亿美元，同比增加13.0%。经营利润为5.575亿美元，同比增加27.6%。新东方股东应占净利润为4.13亿美元，同比增加13.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432376.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01276","VXUS","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629127880","title":"创新药收入占比首破六成，恒瑞医药Q1营收81亿元，净利同增22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629127880","media":"华尔街见闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629127880?lang=zh_cn&edition=full","pubTime":"2026-04-22 18:22","pubTimestamp":1776853336,"startTime":"0","endTime":"0","summary":"恒瑞医药一季报显示，公司实现营收81.41亿元，同比增长12.98%；归母净利润22.82亿元，同比增长21.78%。创新药销售收入占比首次突破六成，达61.69%，其中非肿瘤产品收入同比增长92.13%，多元化趋势明显。报告期内累计研发投入22.24亿元，3项创新成果获批，8项新药上市申请获受理，管线推进节奏加快。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3770612","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"创新药收入占比首破六成，恒瑞医药Q1营收81亿元，净利同增22%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","600276","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629019821","title":"恒瑞医药：第一季度净利润22.82亿元，同比增长21.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629019821","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629019821?lang=zh_cn&edition=full","pubTime":"2026-04-22 17:12","pubTimestamp":1776849143,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月22日，恒瑞医药（HK1276）公告，2026年第一季度营业收入81.41亿元，同比增长12.98%。净利润22.82亿元，同比增长21.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223714119581.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223714119581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["600276","01276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628479357","title":"恒瑞医药(01276)：HRS9531注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2628479357","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628479357?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:32","pubTimestamp":1776684735,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药 发布公告，近日，江苏恒瑞医药股份有限公司子公司福建盛迪医药有限公司收到国家药品监督管理局核准签发关于HRS9531注射液的《药物临床试验批准通知书》，将于近期开展临床试验。HRS9531注射液是以HRS9531为主要活性成分，具有全球自主知识产权的新型靶向抑胃肽受体和胰高血糖素样肽-1受体的双激动剂，其用于成人长期体重管理的上市申请已于2025年9月获国家药监局受理。截至目前，HRS9531相关项目累计研发投入约6.32亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","LU0405327494.USD","LU2580892862.HKD","LU1255011170.USD","LU2488822045.USD","BK1191","BK0196","BK0012","BK0239","LU0359201612.USD","LU1328615791.USD","LU1820825898.SGD","BK0060","LU2097828714.EUR","LU2495084118.USD","LU1064130708.USD","BK0183","LU0359202008.SGD","LU2543165471.USD","LU0359201885.HKD","LU2328871848.SGD","LU0405327148.USD","LU1997244956.HKD","LU2148510915.USD","LU2097828557.USD","LU2289578879.USD","01276","LU1969619763.USD","LU1781817850.SGD","LU1023057109.AUD","LU1997245177.USD","LU2097828631.EUR","LU2097828805.USD","LU1146622755.USD","600276","LU1064131003.USD","LU1655091616.SGD","LU2097828474.EUR","LU2580892789.USD","LU1997245094.SGD","BK0188","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628679211","title":"恒瑞医药将于5月27日派发末期股息每10股2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628679211","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628679211?lang=zh_cn&edition=full","pubTime":"2026-04-20 08:56","pubTimestamp":1776646560,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n 恒瑞医药（01276）发布公告，该公司将于2026年5月27日派发末期股息每10股2元人民币。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-04-20/doc-inhvayqk0731739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0405327494.USD","LU2289578879.USD","BK0028","BK4588","LU2328871848.SGD","BK0188","LU2495084118.USD","LU0359201612.USD","LU1655091616.SGD","LU1328615791.USD","LU2097828557.USD","LU2580892789.USD","LU0405327148.USD","LU1255011170.USD","LU2148510915.USD","LU2580892862.HKD","BK0183","LU2488822045.USD","LU1781817850.SGD","BK0196","BK4585","LU1580142542.USD","VIG","BK0060","LU2543165471.USD","BK0012","BK1191","LU2097828474.EUR","LU1064131003.USD","LU1997245094.SGD","LU2097828631.EUR","LU2097828714.EUR","LU1997244956.HKD","LU1064130708.USD","600276","LU0359201885.HKD","LU1023057109.AUD","LU1146622755.USD","01276","LU1820825898.SGD","BK0239","LU2097828805.USD","LU1969619763.USD","LU1997245177.USD","LU0359202008.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628766952","title":"减肥药企业Kailera纳斯达克上市：市值31亿美元 恒瑞医药成大赢家","url":"https://stock-news.laohu8.com/highlight/detail?id=2628766952","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628766952?lang=zh_cn&edition=full","pubTime":"2026-04-19 15:45","pubTimestamp":1776584754,"startTime":"0","endTime":"0","summary":"减肥药企业Kailera Therapeutics(股票代码：“KLRA”）日前在美国纳斯达克上市，发行价为16美元，发行3906万股，募资总额为6.24亿美元。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391221034231146037652788.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260419/6391221034231146037652788.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33340/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["LU1328615791.USD","SQQQ","JEPQ","LU0405327494.USD","QQQE","LU2580892789.USD","LU1969619763.USD","01276","LU0359201612.USD","BK1191","LU1655091616.SGD","LU1781817850.SGD","BK0060","FTEC","LU2097828631.EUR","LU2148510915.USD","LU2495084118.USD","LU2543165471.USD","QDTE","LU0359202008.SGD","BK0196","QID","QLD","TQQY","QYLG","MNQmain","QQQM","BK0183","BK0028","QQQ","LU1146622755.USD","LU2097828714.EUR","LU0405327148.USD","BK1147","LU1997245177.USD","LU2289578879.USD","LU1580142542.USD","600276","BK4007","LU1064130708.USD","LU2580892862.HKD","KLRA","QQQJ","QQQY","LU1064131003.USD","LU1255011170.USD","LU1997244956.HKD","GPIQ","TQQQ","LU1023057109.AUD","BK0012","LU0359201885.HKD","LU1820825898.SGD","PSQ","ONEQ","NQmain","LU2488822045.USD","BK0239","BK0188","LU1997245094.SGD","LU2097828805.USD","LU2097828557.USD","LU2097828474.EUR","LU2328871848.SGD","IYW","QQQA","NVIW.SI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628542204","title":"恒瑞医药(01276)将于5月27日派发末期股息每10股2元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628542204","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628542204?lang=zh_cn&edition=full","pubTime":"2026-04-17 21:36","pubTimestamp":1776432977,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(01276)发布公告，由于2025年利润分派方案已于股东会获股东批准，董事会欣然宣布，向全体股东派发现金股息每10股人民币2元(含税)(2025年末期股息)。 2025年末期股息将派付予于2026年5月11日(星期一)(记录日期)名列本公司H股股东名册的H股股东。2025年末期股息预期于2026年5月27日(星期三)向H股股东派发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430219.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828805.USD","LU2289578879.USD","LU1997245177.USD","LU1781817850.SGD","BK0183","LU2097828631.EUR","LU0405327148.USD","LU1023057109.AUD","LU1064130708.USD","BK0012","LU2097828474.EUR","01276","LU1064131003.USD","BK0196","LU1820825898.SGD","LU1655091616.SGD","BK0028","BK0239","LU1255011170.USD","LU2097828714.EUR","BK4588","LU2495084118.USD","LU1328615791.USD","LU2097828557.USD","BK1191","LU2328871848.SGD","LU2543165471.USD","LU1997245094.SGD","600276","LU0359202008.SGD","LU2488822045.USD","LU2580892789.USD","LU1580142542.USD","LU1997244956.HKD","BK4585","BK0188","BK0060","LU0359201612.USD","LU1146622755.USD","LU2580892862.HKD","VIG","LU2148510915.USD","LU1969619763.USD","LU0405327494.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778230802219,"stockEarnings":[{"period":"1week","weight":-0.0037},{"period":"1month","weight":-0.0435},{"period":"3month","weight":-0.0633},{"period":"6month","weight":-0.1283},{"period":"1year","weight":0.0459},{"period":"ytd","weight":-0.0989}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0745},{"period":"3month","weight":0.0282},{"period":"6month","weight":0.0457},{"period":"1year","weight":0.2505},{"period":"ytd","weight":0.0532}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏恒瑞医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"458309人(较上一季度增加1.93%)","perCapita":"13918股","listingDate":"2000-10-18","address":"江苏省连云港市连云区经济技术开发区黄河路38号","registeredCapital":"663719万元","survey":" 江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。","listedPrice":11.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,600276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(600276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(600276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}